BIIB

Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Stay connected…
Read More...

U.S. Food and Drug Administration Commissioner Robert Califf defended his agency’s…
Read More...

A sweeping Medicare rule issued last year will keep the newly approved Alzheimer’s disease drug Leqembi out of reach of…
Read More...

The Food and Drug Administration granted conditional approval to the drug, called lecanemab, based on an early study…
Read More...

The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a…
Read More...

Biogen Inc. agreed to pay $900 million to settle allegations that…
Read More...

Biogen Inc. Chief Executive Michel Vounatsos will resign…
Read More...

The advisory committee voted 6-to-4 that there wasn’t enough evidence from the single clinical trial to find that Amylyx…
Read More...

Drugmakers and patient advocacy groups are pushing back against a federal proposal to cut off most Medicare…
Read More...

Biogen Inc. BIIB -0.30% is selling its share…
Read More...